Summary

Other Scenarios:

Buyer: Genentech, Inc. (DNA) Last Price: 93.72 Market Cap.: 98.73B
Target: OSI Pharmaceuticals, Inc. (OSIP) Last Price: 36.03 Market Cap.: 2.09B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
Healthcare 807
Biopharmaceuticals 350
Medical Devices   212

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 39)
  • Xolair (Omalizumab)
  • Activase (Alteplase)
  • TNKase (Tenecteplase)
  • Anti-oxLDL Antibody
Target (Total: 13)
  • PSN010 (Glucokinase Activators)
  • PSN357 (Glycogen Phosphlorylase Inhibitor)
  • PSN821 (G-Protein Coupled Receptor 119) Agonist
  • Novantrone (Mitoxantrone Hydrochloride)
Buyer

n/a
Target
  • Gelclair

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 27)
  • Altus Pharmaceuticals Inc. (ALTU)
  • Curis, Inc. (CRIS)
  • PDL BioPharma Inc. (PDLI)
  • Array BioPharma Inc. (ARRY)
Target (Total: 6)
  • Wyeth (WYE)
  • Gilead Sciences, Inc. (GILD)
  • ISIS Pharmaceuticals, Inc. (ISIS)
  • Nektar Therapeutics (NKTR)
Buyer (Total: 18)
  • AmerisourceBergen Corp. (ABC)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • Johnson & Johnson (JNJ)
Target (Total: 5)
  • Genentech, Inc. (DNA)
  • Novartis AG (ADR) (NVS)
  • Merck & Co., Inc. (MRK)
  • Bristol Myers Squibb Co. (BMY)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 11,186 491
Revenue Per Employee 1,328,752.0 805,693.1
Total Revenue 3,707.0 98.4
Total Expenses 2,343.0 73.5
Other Revenue 726.0 14.8
Cost of Revenue 503.0 2.6
SG&A Expense 718.0 24.9
Research & Development 757.0 41.3
Other Operating Expense 365.0 0.0
Operating Income 1,364.0 25.0
Unusual Income 0.0 4.0
LT Debt to Capital 12.94 42.06
Fwd P/E 25.86 19.84
Fwd P/Rev 7.01 5.08
Book Value 15,671.0 571.5
Curr Portion of LTD/Cap Lease 0.0 0.0

Individual Company Summary

Focused

Buyer

Sector Pure-Play (): Healthcare > Biopharmaceuticals

Target

Focused (): Healthcare > Biopharmaceuticals > Oncology

Business Description

Buyer

Genentech, Inc. (Genentech) is a biotechnology company that discovers, develops, manufactures and commercializes pharmaceutical products to treat patients with unmet medical needs. It commercializes multiple biotechnology products and also receives royalties from companies that are licensed to market products based on the Company?s technology. Genentech commercializes various products in the United States, including Avastin, Rituxan, Herceptin, Lucentis, Xolair, Tarceva, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme and Raptiva. The Company?s licensed products include Trastuzumab, Rituximab, Bevacizumab, Dornase alfa, recombinant, Alteplase and Tenecteplase, Somatropin, Daclizumab, Ranibizumab, Etanercept, Adalimumab and Infliximab.

Target

OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's primary focus is oncology and its flagship product is Tarceva (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR). OSI also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company's United Kingdom subsidiary. Roche Holding Ltd. and OSI announced that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC), which is aggravated following chemotherapy. In December 2008, the Company acquired from 7TM Pharma A/S, a number of early stage research assets and a G-Protein coupled receptor (GPCR), technology platform.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 87.02 97.54
Operating Margin % 39.72 35.14
Quick Ratio 2.29 10.04
Current Ratio 3.25 11.3
Coverage Ratio -0.02 0.01
Total Assets 21,787.0 1,093.1
Return on Equity % 21.87 81.64
Return on Assets % 15.73 42.69
Cash+ ST Inv. Per Share 5.82 7.7
Total Debt 2,829.0 415.0
Total Debt to Equity % 18.05 72.6
Total Debt to Tangible Equity % 21.64 79.01
Debt to Asset % 12.98 37.96

Product Summary

Sector Buyer Target
Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Medical Devices  
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
Healthcare
Biopharmaceuticals
Allergies  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.

Buyer Products:

  • Xolair (Omalizumab)
  
Upper Respiratory  
Monoclonal Antibodies
Therapeutics that treat allergic reactions by specifically binding and inhibiting inflammatory substances.

Buyer Products:

  • Xolair (Omalizumab)
  
Cardiovascular System  
Heart Disorders  
Myocardial Infarction (MI)  
Thrombolytic Agents
Therapeutics that treat the ineffective pumping of the heart by dissolving blood clots in blood vessels.

Buyer Products:

  • Activase (Alteplase)
  • TNKase (Tenecteplase)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Anti-oxLDL Antibody
  
Vascular Disorders  
Stroke  
Thrombolytic Agents
Therapeutics that prevent or treat damage to nerve cells of the brain by dissolving blood clots in blood vessels.

Buyer Products:

  • Activase (Alteplase)
  
Thromboembolism  
Thrombolytic Agents
Therapeutics that treat obstructions of blood vessels by dissolving blood clots.

Buyer Products:

  • TNKase (Tenecteplase)
  • Activase (Alteplase)
  
Dermatology  
Lesion/Scaling Disorders  
Psoriasis  
Monoclonal Antibodies
Therapeutics that treat psoriasis by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.

Buyer Products:

  • Raptiva (Efalizumab)
  
Digestive System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Ocrelizumab/R1594 (Humanized Anti-CD20 Monoclonal Antibody)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Anti-beta 7
  
Endocrinology/Metabolism
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Target Products:

  • PSN010 (Glucokinase Activators)
  • PSN357 (Glycogen Phosphlorylase Inhibitor)
  
Pituitary Gland Disorders  
Severe Short Stature  
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.

Buyer Products:

  • Nutropin/Nutropin AQ (Recombinant Somatropin (Human Growth Hormone))
  
Turner`s Syndrome  
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.

Buyer Products:

  • Nutropin/Nutropin AQ (Recombinant Somatropin (Human Growth Hormone))
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.

Target Products:

  • PSN821 (G-Protein Coupled Receptor 119) Agonist
  
Immunology
Autoimmune Disorders
Arthritis  
Rheumatoid Arthritis (RA)  
Immunotherapy  
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.

Buyer Products:

  • Ocrelizumab/R1594 (Humanized Anti-CD20 Monoclonal Antibody)
  • Rituxan (Rituximab)
  
Lupus Erythematosus  
Systemic (SLE)  
Monoclonal Antibodies
Therapeutics that treat systemic lupus by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.

Buyer Products:

  • Ocrelizumab/R1594 (Humanized Anti-CD20 Monoclonal Antibody)
  • Rituxan (Rituximab)
  
Multiple Sclerosis (MS)  
Topoisomerase II Inhibitors
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths an enzyme that inhibits the proliferation of cells.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Psoriasis  
Monoclonal Antibodies
Therapeutics that treat psoriasis by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.

Buyer Products:

  • Raptiva (Efalizumab)
  
Wegener`s Granulomatosis  
Monoclonal Antibodies
Therapeutics that treat Wegener's Granulomatosis by interfering with specific immune pathways implicated in the progression of the disease.

Buyer Products:

  • Rituxan (Rituximab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Ocrelizumab/R1594 (Humanized Anti-CD20 Monoclonal Antibody)
  • MTRX1011A (anti-CD4 Monoclonal Antibody)
  • Anti-IFN alpha
  • Rituxan (Rituximab)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Anti-beta 7
  
Musculoskeletal System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MTRX1011A (anti-CD4 Monoclonal Antibody)
  
Skeletal Disorders  
Joint Disorders  
Rheumatoid Arthritis (RA)  
Immunotherapy  
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.

Buyer Products:

  • Ocrelizumab/R1594 (Humanized Anti-CD20 Monoclonal Antibody)
  • Rituxan (Rituximab)
  
Neurology
Neuromuscular Disorders  
Multiple Sclerosis (MS)  
Topoisomerase II Inhibitors
Therapeutics that treat multiple sclerosis by inhibiting a key enzyme involved with cell division.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Ocrelizumab/R1594 (Humanized Anti-CD20 Monoclonal Antibody)
  • Rituxan (Rituximab)
  
Oncology
Breast Cancer  
Localized  
Monoclonal Antibodies
Therapeutics that treat breast cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Herceptin (Trastuzumab)/Avastin (Bevacizumab)
  • Herceptin (Trastuzumab)
  
Metastatic  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of breast cancer cells and inhibit the cancer cells' growth and induce their death.

Buyer Products:

  • Herceptin (Trastuzumab)/Omnitarg (Pertuzumab)
  • Trastuzumab-DM1
  • Herceptin (Trastuzumab)
  • Avastin (Bevacizumab)
  
Digestive System
Colon Cancer/Colorectal Cancer
Metastatic
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage colorectal cancer by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.

Target Products:

  • Tarceva (Erlotinib)
  
Monoclonal Antibodies
Therapeutics that treat colorectal cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)
  
Pancreatic Cancer
Metastatic
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the pancreas by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.

Buyer Products:

  • Tarceva (Erlotinib)

Target Products:

  • Tarceva (Erlotinib)
Hematology
Leukemia (White Blood Cell Cancer)
Lymphoid  
Chronic  
Lymphocytic (CLL)  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of leukemia cells and thereby induce their death.

Buyer Products:

  • Rituxan (Rituximab)
  
Myeloid  
Acute  
Erythroleukemic  
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature red blood cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Monocytic  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers affecting mononuclear cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Myeloblastic  
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by inhibiting a specific enzyme needed for transcription and replication of DNA.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Myelogenous (AML)  
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Promyelocytic (APL)  
Topoisomerase II Inhibitors
Therapeutics that treat and manage promyelocytic leukemia by inhibiting a specific enzyme needed for transcription and replication of DNA.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Lymphoma (Lymphatic Cancer)  
Non-Hodgkin`s Lymphoma (NHL)  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of lymphoma cells and thereby induce their death.

Buyer Products:

  • Rituxan (Rituximab)/Avastin (Bevacizumab)
  • Rituxan (Rituximab)
  
Neurology  
Brain Cancer  
Glioma  
Glioblastoma  
Monoclonal Antibodies
Therapeutics that treat and manage tumors of the glial cells by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • Trastuzumab-DM1
  • ABT-869 (VEGFR Kinase Inhibitor)
  • ABT-263 (Bcl-2 Antagonist)
  • SGN-40 (Anti-CD40 Antibody)
  • GDC-0449 (Hedgehog Systemic Small Molecule Antagonist)
  • XL518 (MEK Inhibitor)
  • Avastin (Bevacizumab)/Sutent (Sunitinib)
  • P13 Kinase Inhibitor
  • GA101 (Humanized Anti-CD20 Monoclonal Antibody)
  • rhApo2L/TRAIL (PRO1762)
  • Omnitarg (Pertuzumab)
  • Avastin (Bevacizumab)
  • Tarceva (Erlotinib)
  • Apomab (Proapoptotic Receptor Agonist)
  • IAP Antagonist (Inhibitors Of Apoptosis)
  • MetMAb
  • Erlotinib/Pertuzumab Combination Therapy

Target Products:

  • OSI-930 (c-kit/VEGFR-2 Inhibitor)
  • OSI-027 (mTOR Inhibitor)
  • Avastin (Bevacizumab)/Tarceva (Erlotinib HCl)
  • OSI-906 (Insulin-Like Growth Factor-1 Receptor Inhibitor)
  • CP-868,596 (Platelet-Derived Growth Factor Receptor Inhibitor)
  • Tarceva (Erlotinib)
  • OSI632/Formerly CP 547,632 (VEGFR Inhibitor)
  • Novantrone (Mitoxantrone Hydrochloride)
Respiratory System/Thoracic
Lung Cancer
Non Small Cell Lung Cancer (NSCLC)
EGFR-TK Inhibitors/Monoclonal Antibodies
Therapeutics that treat lung cancer by blocking the tyrosine kinase enzyme and by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)/Tarceva (Erlotinib HCl)

Target Products:

  • Avastin (Bevacizumab)/Tarceva (Erlotinib HCl)
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the tyrosine kinase enzyme by switching off the signals from the epidermal growth factor receptors.

Buyer Products:

  • Tarceva (Erlotinib)

Target Products:

  • Tarceva (Erlotinib)
Monoclonal Antibodies
Therapeutics that treat lung cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)
  
Urology
Ovarian Cancer
Metastatic
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage ovarian cancers by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.

Target Products:

  • Tarceva (Erlotinib)
  
Monoclonal Antibodies
Therapeutics that treat and manage ovarian cancers that have spread beyond their original tumor site by binding to specific structures on the surface of the tumor, eliciting a reaction which results in tumor cell death.

Buyer Products:

  • Avastin (Bevacizumab)
  
Prostate Cancer
Metastatic  
Monoclonal Antibodies
Therapeutics that treat prostate cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)
  
Palliative Agents  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of the prostate gland by inhibiting a specific enzyme needed for transcription and replication of DNA but are not curative.

Target Products:

  • Novantrone (Mitoxantrone Hydrochloride)
  
Ophthalmology  
Degenerative Disorders  
Edema  
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular edema by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.

Buyer Products:

  • Lucentis (Ranibizumab)
  
Macular Degeneration (AMD)  
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular degeneration by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.

Buyer Products:

  • Lucentis (Ranibizumab)
  
Retinopathy  
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat general retinopathy by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.

Buyer Products:

  • Lucentis (Ranibizumab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Lucentis (Ranibizumab)
  
Respiratory System  
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Prophylactic Treatments  
Monoclonal Antibodies
Therapeutics that treat asthma with monoclonal antibodies.

Buyer Products:

  • Xolair (Omalizumab)
  
Cystic Fibrosis (CF)  
Recombinant Human Deoxyribonuclease I
Therapeutics that relieve symptoms of cystic fibrosis by hydrolyzing the DNA in the sputum of cystic fibrosis patients thus reducing viscosity of the secretions and aiding lung function.

Buyer Products:

  • Pulmozyme (Dornase Alfa)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Humanized Anti-IL13 Antibody
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Anti-OX40L
  
Surgery  
Cardiovascular System  
Complications  
Peripheral Arterial Occlusion  
Thrombolytic Agents
Therapeutics that treat diseases of the blood vessels outside the heart by dissolving blood clots.

Buyer Products:

  • Cathflo Activase (Alteplase)
  
Weight Management  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.

Target Products:

  • PSN602 (Serotonin/Norepinephrine Reuptake Inhibitor)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.

Target Products:

  • PSN821 (G-Protein Coupled Receptor 119) Agonist
  
Medical Devices  
Medical Supplies  
Treatment  
Wound Management/First Aid  
Drainage/Hydration
Medical devices designed to irrigate, moisturize and remove excess fluids from wounds and wound surface.

Target Products:

  • Gelclair
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Johnson & Johnson n/a 143,004.165 11.04 11.15 2.24 2.25 9.65
Pfizer Inc. n/a 91,929.443 11.35 7.14 1.90 1.94 5.00
Sanofi-Aventis SA (ADR) n/a 74,587.395 15.33 7.36 2.05 2.01 40.91
Abbott Laboratories n/a 73,467.508 15.05 12.92 2.49 2.33 31.38
Wyeth n/a 56,052.614 12.69 11.71 2.45 2.45 3.87
Amgen, Inc. n/a 50,271.330 11.98 10.71 3.35 3.36 8.30
Bristol Myers Squibb Co. n/a 40,560.139 7.73 10.79 1.97 1.91 6.48
Eli Lilly & Co. n/a 37,400.471 n/a 7.67 1.84 1.70 13.95
Onyx Pharmaceuticals, Inc. n/a 1,576.699 809.88 30.51 8.11 7.00 3.32
Regeneron Pharmaceuticals, Inc. n/a 1,075.687 n/a -13.03 4.51 4.20 2.57
MannKind Corporation n/a 334.623 n/a -1.66 16,442.10 7.39 3.86
Insmed Incorporated n/a 111.470 n/a n/a 9.53 n/a n/a
Ariad Pharmaceuticals, Inc. n/a 107.947 n/a -1.19 15.24 6.43 n/a
Peregrine Pharmaceuticals n/a 84.377 n/a -5.71 7.55 6.12 22.25
XOMA Limited n/a 54.053 n/a -0.95 0.79 0.89 n/a
Spectrum Pharmaceuticals, Inc. n/a 47.710 n/a -2.51 2.30 1.94 1.03
Cell Therapeutics, Inc. n/a 31.336 n/a -0.12 3.50 11.95 n/a
Threshold Pharmaceuticals, Inc. n/a 19.788 n/a -1.26 13.74 n/a 0.92
YM BioSciences Inc. (USA) n/a 15.634 n/a -1.47 2.56 n/a 0.46
IRIDEX Corporation n/a 7.181 n/a n/a 0.15 n/a 0.70
Vion Pharmaceuticals, Inc. n/a 4.165 n/a n/a 49.04 n/a n/a
Buyer
  Johnson & Johnson n/a 143,004.165 11.04 11.15 2.24 2.25 9.65
Pfizer Inc. n/a 91,929.443 11.35 7.14 1.90 1.94 5.00
Target
  Johnson & Johnson n/a 143,004.165 11.04 11.15 2.24 2.25 9.65
Roche Holding Ltd. (ADR) n/a 110,235.519 14.24 13.04 2.80 2.70 4.40

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Altus Pharmaceuticals Inc. 88.00% 4.670 n/a n/a 2.16 n/a 0.13
Curis, Inc. 76.00% 75.111 n/a -5.64 8.98 9.04 2.66
PDL BioPharma Inc. 68.00% 623.434 9.12 5.13 2.12 2.27 n/a
Array BioPharma Inc. 54.10% 123.559 n/a -1.11 4.54 5.13 n/a
ImmunoGen, Inc. 34.00% 322.027 n/a -10.48 9.33 9.46 7.82
Exelixis, Inc. 16.00% 485.105 n/a -3.27 4.12 3.21 n/a
Sangamo Biosciences, Inc. 3.10% 167.551 n/a -8.33 10.35 9.16 3.02
Alexandria Real Estate Equities, Inc. 1.70% 1,062.332 10.77 6.02 2.31 2.57 0.64
Actelion Ltd. 0.50% n/a n/a 17.97 n/a n/a n/a
Novartis AG (ADR) n/a 85,294.364 10.41 10.16 2.00 2.00 2.89
Abbott Laboratories n/a 73,467.508 15.05 12.92 2.49 2.33 31.38
Medco Health Solutions Inc. n/a 18,983.003 17.21 14.20 0.37 0.35 n/a
Biogen Idec Inc. n/a 14,853.722 19.00 12.50 3.63 3.41 5.93
Agilent Technologies Inc. n/a 4,982.048 7.82 14.89 0.90 1.10 2.93
Boston Properties, Inc. n/a 4,232.183 33.79 8.23 2.84 3.40 1.20
OSI Pharmaceuticals, Inc. n/a 2,086.885 4.43 19.84 5.50 5.08 3.97
Seattle Genetics, Inc. n/a 822.747 n/a -9.16 23.35 22.36 10.41
Dendreon Corporation n/a 394.771 n/a -6.27 3,456.54 438.10 14.62
Harte-Hanks, Inc. n/a 304.719 4.86 7.74 0.28 0.32 n/a
Target
  Wyeth n/a 56,052.614 12.69 11.71 2.45 2.45 3.87
Gilead Sciences, Inc. n/a 40,328.414 20.05 17.79 7.56 6.44 9.71
ISIS Pharmaceuticals, Inc. n/a 1,316.558 n/a -96.93 12.28 10.74 38.76
Nektar Therapeutics n/a 424.603 n/a -3.35 4.71 4.34 3.74
Enzon Pharmaceuticals, Inc. n/a 274.917 n/a -23.44 1.40 1.41 n/a
Cadus Corporation n/a 19.716 n/a n/a 197.37 n/a 0.77

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Novartis AG (ADR) n/a 85,294.364 10.41 10.16 2.00 2.00 2.89
Buyer
  AmerisourceBergen Corp. 55.00% 4,656.649 18.49 9.55 0.07 0.07 n/a
McKesson Corporation 17.00% 9,592.342 11.30 8.55 0.09 0.09 3.89
Cardinal Health, Inc. 13.00% 11,175.784 9.02 8.85 0.12 0.12 5.75
Johnson & Johnson n/a 143,004.165 11.04 11.15 2.24 2.25 9.65
Roche Holding Ltd. (ADR) n/a 110,235.519 14.24 13.04 2.80 2.70 4.40
Novartis AG (ADR) n/a 85,294.364 10.41 10.16 2.00 2.00 2.89
Abbott Laboratories n/a 73,467.508 15.05 12.92 2.49 2.33 31.38
Amgen, Inc. n/a 50,271.330 11.98 10.71 3.35 3.36 8.30
Bayer AG (ADR) n/a 38,744.491 5.36 8.48 0.85 0.89 n/a
Seattle Genetics, Inc. n/a 822.747 n/a -9.16 23.35 22.36 10.41
InterMune, Inc. n/a 752.810 n/a -6.48 15.63 16.37 n/a
Medarex inc. n/a 615.543 n/a -3.74 11.77 11.72 2.47
Dyax Corp. n/a 152.048 n/a -2.88 3.50 4.27 n/a
Insmed Incorporated n/a 111.470 n/a n/a 9.53 n/a n/a
Peregrine Pharmaceuticals n/a 84.377 n/a -5.71 7.55 6.12 22.25
Inhibitex, Inc. n/a 10.845 n/a -0.67 3.44 5.24 0.36
Boehringer Ingelheim GmbH n/a n/a n/a n/a n/a n/a n/a
Zenyaku Kogyo Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Target
  Genentech, Inc. n/a 98,725.960 28.81 25.86 7.36 7.01 7.55
Novartis AG (ADR) n/a 85,294.364 10.41 10.16 2.00 2.00 2.89
Merck & Co., Inc. n/a 56,318.465 7.21 7.99 2.36 2.30 3.35
Bristol Myers Squibb Co. n/a 40,560.139 7.73 10.79 1.97 1.91 6.48
Eli Lilly & Co. n/a 37,400.471 n/a 7.67 1.84 1.70 13.95

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Roche Holding Ltd. (ADR) n/a 110,235.519 14.24 13.04 2.80 2.70 4.40
Novartis AG (ADR) n/a 85,294.364 10.41 10.16 2.00 2.00 2.89
Abbott Laboratories n/a 73,467.508 15.05 12.92 2.49 2.33 31.38
Wyeth n/a 56,052.614 12.69 11.71 2.45 2.45 3.87
Buyer
  Johnson & Johnson n/a 143,004.165 11.04 11.15 2.24 2.25 9.65
Roche Holding Ltd. (ADR) n/a 110,235.519 14.24 13.04 2.80 2.70 4.40
Target
  Roche Holding Ltd. (ADR) n/a 110,235.519 14.24 13.04 2.80 2.70 4.40
Genentech, Inc. n/a 98,725.960 28.81 25.86 7.36 7.01 7.55
Pfizer Inc. n/a 91,929.443 11.35 7.14 1.90 1.94 5.00
Novartis AG (ADR) n/a 85,294.364 10.41 10.16 2.00 2.00 2.89
Abbott Laboratories n/a 73,467.508 15.05 12.92 2.49 2.33 31.38
Merck & Co., Inc. n/a 56,318.465 7.21 7.99 2.36 2.30 3.35
Wyeth n/a 56,052.614 12.69 11.71 2.45 2.45 3.87
Bristol Myers Squibb Co. n/a 40,560.139 7.73 10.79 1.97 1.91 6.48
Gilead Sciences, Inc. n/a 40,328.414 20.05 17.79 7.56 6.44 9.71
Eli Lilly & Co. n/a 37,400.471 n/a 7.67 1.84 1.70 13.95
ISIS Pharmaceuticals, Inc. n/a 1,316.558 n/a -96.93 12.28 10.74 38.76
Nektar Therapeutics n/a 424.603 n/a -3.35 4.71 4.34 3.74
Enzon Pharmaceuticals, Inc. n/a 274.917 n/a -23.44 1.40 1.41 n/a
Cadus Corporation n/a 19.716 n/a n/a 197.37 n/a 0.77
Transgenomic, Inc. n/a 14.265 n/a 26.00 0.59 n/a 1.15
Catalent Pharma Solutions n/a n/a n/a n/a n/a n/a n/a
Schwarz Pharma, Inc. n/a n/a n/a n/a n/a n/a n/a
Dipharma Francis Srl n/a n/a n/a n/a n/a n/a n/a
AVEO Pharmaceuticals, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 10,530.0 364.6 10,894.6
Other Revenue 2,888.0 14.8 2,902.8
Total Revenue 13,418.0 379.4 13,797.4
Cost of Revenue 1,742.0 9.3 1,751.3
SG&A Expense 2,405.0 94.9 2,499.9
Depreciation & Amortization 0.0 2.5 2.5
Research & Development 2,800.0 135.3 2,935.3
Interest Expense 0.0 0.0 0.0
Other Operating Expense 1,401.0 0.0 1,401.0
Unusual Expense (Income) -259.0 4.0 -255.0
Total Expenses 8,089.0 246.1 8,335.1
Operating Income 5,329.0 133.3 5,462.3
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng -83.0 1.0 -82.0
Other, Net 185.0 -1.2 183.8
Income Before Taxes 5,431.0 133.1 5,564.1
Income Taxes 2,004.0 -333.5 1,670.5
Income After Taxes 3,427.0 466.6 3,893.6
Net Income - Excl. Xord. Items 3,427.0 466.6 3,893.6
Discontinued Operations 0.0 4.9 4.9
Net Income - Incl. Xord. Items 3,427.0 471.5 3,898.5
Income Avail. to Common 3,427.0 471.5 3,898.5
Share Items
Basic Avg. Shares Outstanding 1,052.0 57.6 1,109.6
Basic EPS - Excl. Xord. Items 3.26 8.10 3.51
Basic EPS - Incl. Xord. Items 3.26 8.18 3.51
Full Dilution Adjustment 0.0 3.3 3.3
Fully Diluted Shares Outstanding 1,065.0 66.7 1,131.7
F.D. EPS - Excl. Xord. Items 3.22 7.00 3.44
F.D. EPS - Incl. Xord. Items 3.22 7.07 3.44
Balance Sheet
Assets
Cash and Equivalents 4,533.0 272.9 4,805.9
ST Investments 1,665.0 240.3 1,905.3
Accounts Receivable 902.0 100.2 1,002.2
Inventory 1,299.0 20.1 1,319.1
Prepayments and Advances 135.0 6.7 141.7
Other Current Assets 500.0 50.0 550.0
Current Assets 10,073.0 690.4 10,763.4
Accum D&A 0.0 0.0 0.0
PPE, Net 5,404.0 43.4 5,447.4
Goodwill & Intangibles 2,598.0 46.4 2,644.4
Long Term Investments 3,347.0 0.0 3,347.0
Other Assets 0.0 0.0 0.0
Other LT Assets 365.0 312.9 677.9
Total Assets 21,787.0 1,093.1 22,880.1
Liabilities
Accounts Payable 228.0 0.0 228.0
Payable/Accrued 0.0 49.1 49.1
Accrued Expenses 2,099.0 0.0 2,099.0
ST Debt 500.0 0.0 500.0
Other (Current) Liabilities 268.0 12.1 280.1
Current Liab. 3,095.0 61.1 3,156.1
LT Debt 2,329.0 415.0 2,744.0
Total LT Debt 2,329.0 415.0 2,744.0
Other LT Liab. 692.0 45.4 737.4
Total Liabilities 6,116.0 521.5 6,637.5
Shareholders Equity
Common Stock 21.0 0.6 21.6
Additional Paid in Capital 12,044.0 1,693.3 13,737.3
Retained Earnings 3,482.0 -1,016.2 2,465.8
Treasure Stock 0.0 -102.2 -102.2
Other Equity 124.0 -3.9 120.1
Total Equity 15,671.0 571.5 16,242.5
Total Liab. & Equity 21,787.0 1,093.1 22,880.1
Shares Outstanding 1,053.0 57.7 1,110.7
Cash Flow
Operating Cash Flow
CF Net Income 3,427.0 471.5 3,898.5
CF Depreciation 592.0 13.2 605.2
CF Deferred Taxes 90.0 0.0 90.0
Other Non-Cash Items 50.0 -297.6 -247.6
Change in Working Capital -204.0 -48.1 -252.1
Total Cash From Operating Activities 3,955.0 138.9 4,093.9
Investing Cash Flow (not calculated)
Capital Expenditures -751.0 -17.9 -768.9
Other Investing Cash Flows -916.0 -101.3 -1,017.3
Total Cash From Investing Activities -1,667.0 -119.1 -1,786.1
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock -100.0 -48.0 -148.0
Purchase and Retirement of Debt -99.0 200.0 101.0
Other Financing Cash Flow -70.0 -9.5 -79.5
Total Cash From Financing Activities -269.0 92.5 -176.5
Exchange Rate Effects 0.0 -2.1 -2.1
Net Change in Cash 2,019.0 110.2 2,129.2
Cash Taxes Paid 1,779.0 2.1 1,781.1
Cash Interest Paid 74.0 9.8 83.8